Alector (ALEC) Total Current Liabilities (2018 - 2026)
Alector's (ALEC) quarterly Total Current Liabilities came in at $34.2 million in Q2 2026, down 59.41% year-over-year from $84.4 million in Q2 2025, and down 16.43% quarter-over-quarter from $41.0 million in Q1 2026.
Analysis
Alector (ALEC) Total Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Total Current Liabilities for 9 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Current Liabilities fell 59.41% year-over-year to $34.2 million in Q2 2026; TTM through Jun 2026 was $34.2 million, a 59.41% decrease from a year earlier, with the FY2025 full-year figure at $69.5 million, down 44.42% from the prior year.
- Total Current Liabilities was $34.2 million for Q2 2026 at Alector, down from $41.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $177.9 million in Q4 2023 and troughed at $34.2 million in Q2 2026.
- A 5-year average of $117.3 million and a median of $128.7 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 123.03% in 2022 and slumped 62.68% in 2026, its largest moves.
- Over 5 years, Total Current Liabilities stood at $93.8 million in 2022, then surged by 89.69% to $177.9 million in 2023, then retreated by 29.72% to $125.1 million in 2024, then plunged by 44.42% to $69.5 million in 2025, then plunged by 50.74% to $34.2 million in 2026.
- The last three Total Current Liabilities figures came in at $34.2 million (Q2 2026), $41.0 million (Q1 2026), and $69.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 34.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.24 Mn |
| Mar 31, 2026 | 40.97 Mn |
| Dec 31, 2025 | 69.50 Mn |
| Sep 30, 2025 | 79.96 Mn |
| Jun 30, 2025 | 84.35 Mn |
| Mar 31, 2025 | 109.77 Mn |
| Dec 31, 2024 | 125.06 Mn |
| Sep 30, 2024 | 142.53 Mn |
| Jun 30, 2024 | 147.68 Mn |
| Mar 31, 2024 | 164.92 Mn |
| Dec 31, 2023 | 177.95 Mn |
| Sep 30, 2023 | 155.40 Mn |
| Jun 30, 2023 | 132.27 Mn |
| Mar 31, 2023 | 99.30 Mn |
| Dec 31, 2022 | 93.81 Mn |
| Sep 30, 2022 | 160.89 Mn |
| Jun 30, 2022 | 149.41 Mn |
| Mar 31, 2022 | 142.88 Mn |
| Dec 31, 2021 | 139.56 Mn |
| Sep 30, 2021 | 132.82 Mn |